Literature DB >> 25422267

Requirement for Serratia marcescens cytolysin in a murine model of hemorrhagic pneumonia.

Norberto González-Juarbe1, Chris A Mares1, Cecilia A Hinojosa1, Jorge L Medina1, Angelene Cantwell1, Peter H Dube1, Carlos J Orihuela2, Molly A Bergman1.   

Abstract

Serratia marcescens, a member of the carbapenem-resistant Enterobacteriaceae, is an important emerging pathogen that causes a wide variety of nosocomial infections, spreads rapidly within hospitals, and has a systemic mortality rate of ≤41%. Despite multiple clinical descriptions of S. marcescens nosocomial pneumonia, little is known regarding the mechanisms of bacterial pathogenesis and the host immune response. To address this gap, we developed an oropharyngeal aspiration model of lethal and sublethal S. marcescens pneumonia in BALB/c mice and extensively characterized the latter. Lethal challenge (>4.0 × 10(6) CFU) was characterized by fulminate hemorrhagic pneumonia with rapid loss of lung function and death. Mice challenged with a sublethal dose (<2.0 × 10(6) CFU) rapidly lost weight, had diminished lung compliance, experienced lung hemorrhage, and responded to the infection with extensive neutrophil infiltration and histopathological changes in tissue architecture. Neutrophil extracellular trap formation and the expression of inflammatory cytokines occurred early after infection. Mice depleted of neutrophils were exquisitely susceptible to an otherwise nonlethal inoculum, thereby demonstrating the requirement for neutrophils in host protection. Mutation of the genes encoding the cytolysin ShlA and its transporter ShlB resulted in attenuated S. marcescens strains that failed to cause profound weight loss, extended illness, hemorrhage, and prolonged lung pathology in mice. This study describes a model of S. marcescens pneumonia that mimics known clinical features of human illness, identifies neutrophils and the toxin ShlA as a key factors important for defense and infection, respectively, and provides a solid foundation for future studies of novel therapeutics for this important opportunistic pathogen.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25422267      PMCID: PMC4294263          DOI: 10.1128/IAI.01822-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

Review 1.  Macrophage defences against respiratory tract infections.

Authors:  S B Gordon; R C Read
Journal:  Br Med Bull       Date:  2002       Impact factor: 4.291

Review 2.  Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Conjugative transfer by the virulence system of Legionella pneumophila.

Authors:  J P Vogel; H L Andrews; S K Wong; R R Isberg
Journal:  Science       Date:  1998-02-06       Impact factor: 47.728

4.  In vivo and in vitro emergence of simultaneous resistance to both beta-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens.

Authors:  F W Goldstein; L Gutmann; R Williamson; E Collatz; J F Acar
Journal:  Ann Microbiol (Paris)       Date:  1983 May-Jun

5.  Group B streptococcal beta-hemolysin promotes injury of lung microvascular endothelial cells.

Authors:  R L Gibson; V Nizet; C E Rubens
Journal:  Pediatr Res       Date:  1999-05       Impact factor: 3.756

6.  Pathologic patterns of Serratia marcescens pneumonia.

Authors:  J D Goldstein; J J Godleski; J P Balikian; P G Herman
Journal:  Hum Pathol       Date:  1982-05       Impact factor: 3.466

7.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Authors:  Douglas J Biedenbach; Gary J Moet; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

8.  Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region.

Authors:  K B Laupland; M D Parkins; D B Gregson; D L Church; T Ross; J D D Pitout
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-25       Impact factor: 3.267

9.  Serratia pneumonia presenting as hemoptysis in a patient with sarcoidosis: a case report.

Authors:  Paul Zarogoulidis; Konstantinos Porpodis; Maria Konoglou; Maria Saroglou; Alexandros Mitrakas; Dimitrios Matthaios; Panagiotis Touzopoulos; Konstantinos Archontogeorgis; Andrew Koulelidis; Konstantinos Zarogoulidis; Stavros Tryfon
Journal:  Int J Gen Med       Date:  2011-09-08

10.  Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia.

Authors:  Angela R Boyd; Cecilia A Hinojosa; Perla J Rodriguez; Carlos J Orihuela
Journal:  BMC Microbiol       Date:  2012-05-15       Impact factor: 3.605

View more
  17 in total

1.  Differential susceptibility of airway and ocular surface cell lines to FlhDC-mediated virulence factors PhlA and ShlA from Serratia marcescens.

Authors:  Nicholas A Stella; Kimberly M Brothers; Robert M Q Shanks
Journal:  J Med Microbiol       Date:  2021-02       Impact factor: 2.472

2.  Pore-forming toxin-mediated ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during bacterial pneumonia.

Authors:  Norberto González-Juarbe; Kelley Margaret Bradley; Anukul Taranath Shenoy; Ryan Paul Gilley; Luis Felipe Reyes; Cecilia Anahí Hinojosa; Marcos Ignacio Restrepo; Peter Herman Dube; Molly Ann Bergman; Carlos Javier Orihuela
Journal:  Cell Death Differ       Date:  2017-04-07       Impact factor: 15.828

3.  Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion.

Authors:  Ryan P Gilley; Norberto González-Juarbe; Anukul T Shenoy; Luis F Reyes; Peter H Dube; Marcos I Restrepo; Carlos J Orihuela
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

4.  Sotolon is a natural virulence mitigating agent in Serratia marcescens.

Authors:  Hisham A Abbas; Reham M Goda
Journal:  Arch Microbiol       Date:  2020-09-24       Impact factor: 2.552

5.  Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia.

Authors:  Norberto González-Juarbe; Ryan Paul Gilley; Cecilia Anahí Hinojosa; Kelley Margaret Bradley; Akinobu Kamei; Geli Gao; Peter Herman Dube; Molly Ann Bergman; Carlos Javier Orihuela
Journal:  PLoS Pathog       Date:  2015-12-11       Impact factor: 6.823

Review 6.  Exolysin Shapes the Virulence of Pseudomonas aeruginosa Clonal Outliers.

Authors:  Emeline Reboud; Pauline Basso; Antoine P Maillard; Philippe Huber; Ina Attrée
Journal:  Toxins (Basel)       Date:  2017-11-09       Impact factor: 4.546

7.  Exploring the Anti-quorum Sensing and Antibiofilm Efficacy of Phytol against Serratia marcescens Associated Acute Pyelonephritis Infection in Wistar Rats.

Authors:  Ramanathan Srinivasan; Ramar Mohankumar; Arunachalam Kannappan; Veeramani Karthick Raja; Govindaraju Archunan; Shunmugiah Karutha Pandian; Kandasamy Ruckmani; Arumugam Veera Ravi
Journal:  Front Cell Infect Microbiol       Date:  2017-12-05       Impact factor: 5.293

8.  Pseudomonas aeruginosa ExlA and Serratia marcescens ShlA trigger cadherin cleavage by promoting calcium influx and ADAM10 activation.

Authors:  Emeline Reboud; Stéphanie Bouillot; Sabine Patot; Benoît Béganton; Ina Attrée; Philippe Huber
Journal:  PLoS Pathog       Date:  2017-08-23       Impact factor: 6.823

9.  Capsule Production and Glucose Metabolism Dictate Fitness during Serratia marcescens Bacteremia.

Authors:  Mark T Anderson; Lindsay A Mitchell; Lili Zhao; Harry L T Mobley
Journal:  MBio       Date:  2017-05-23       Impact factor: 7.867

10.  Influenza-Induced Oxidative Stress Sensitizes Lung Cells to Bacterial-Toxin-Mediated Necroptosis.

Authors:  Norberto Gonzalez-Juarbe; Ashleigh N Riegler; Alexander S Jureka; Ryan P Gilley; Jeffrey D Brand; John E Trombley; Ninecia R Scott; Maryann P Platt; Peter H Dube; Chad M Petit; Kevin S Harrod; Carlos J Orihuela
Journal:  Cell Rep       Date:  2020-08-25       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.